Coherus BioSciences Inc (CHRS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $81.21M
Last updated: Nov 17, 2026 at 11:04 AM ET
Coherus BioSciences Inc (CHRS) Financials: Revenue, Profit and Cash Flow
Coherus BioSciences reported revenue of $42.17M for the fiscal year ended Dec 31, 2025, up 59.8% from the year before. That year, net income was $168.02M with a net margin of 398.4%, operating cash flow was -$138.51M and free cash flow was -$138.51M. The quarter ended Sep 30, 2026 had revenue of $14.27M and net income of -$39.33M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue fell from $190.11M, a compound annual decline of 15.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $42.17M | +59.8% | 67.2% | -429.5% | 398.4% |
| Dec 2024 | $26.39M | -89.7% | 66.9% | -756.6% | 108.0% |
| Dec 2023 | $257.24M | +21.9% | 38.2% | -79.0% | -92.5% |
| Dec 2022 | $211.04M | -35.4% | 66.8% | -121.7% | -138.2% |
| Dec 2021 | $326.55M | -31.4% | 82.4% | -80.8% | -87.9% |
| Dec 2020 | $475.82M | +33.6% | 92.1% | 32.9% | 27.8% |
| Dec 2019 | $356.07M | N/A | 95.2% | 30.3% | 25.2% |
| Dec 2018 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2017 | $1.56M | -99.2% | 100.0% | -14918.8% | -15314.0% |
| Dec 2016 | $190.11M | N/A | 100.0% | -61.0% | -67.2% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 489.3% from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42.17M | $26.39M | $257.24M | $211.04M | $326.55M | $475.82M | $356.07M | $0 | $1.56M | $190.11M |
| Cost of revenue | $13.81M | $8.73M | $158.99M | $70.08M | $57.59M | $37.67M | $17.08M | $0 | $0 | $0 |
| Gross profit | $28.36M | $17.66M | $98.25M | $140.96M | $268.96M | $438.16M | $338.99M | $0 | $1.56M | $190.11M |
| Research and development | $108.89M | $91.83M | $109.44M | $199.36M | $363.11M | $142.76M | $94.19M | $110.24M | $162.39M | $254.44M |
| Operating income | -$181.13M | -$199.65M | -$203.20M | -$256.88M | -$263.86M | $156.32M | $107.77M | -$204.42M | -$232.14M | -$115.93M |
| Net income | $168.02M | $28.51M | -$237.89M | -$291.75M | -$287.10M | $132.24M | $89.83M | -$209.41M | -$238.29M | -$127.79M |
| EBITDA | -$170.20M | -$186.75M | -$191.53M | -$242.93M | -$255.34M | $163.24M | $115.81M | -$195.31M | -$224.14M | -$111.89M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.27M | $14.31M | $12.31M | $12.75M | $11.57M | $10.25M | $7.60M | $7.73M | $6.05M | $10.30M | $2.31M | $91.52M |
| Gross profit | $10.18M | $10.06M | $8.50M | $8.70M | $7.85M | $6.86M | $4.95M | $4.98M | $3.32M | $8.49M | $869.00K | $6.96M |
| Operating income | -$33.65M | -$32.33M | -$36.15M | -$45.88M | -$44.33M | -$45.49M | -$45.44M | -$45.38M | -$46.86M | -$39.63M | -$67.79M | -$68.91M |
| Net income | -$39.33M | -$20.63M | -$38.33M | -$37.64M | -$35.53M | $297.77M | -$56.57M | -$50.70M | -$10.75M | -$12.92M | $102.88M | -$79.65M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $38.88M by $50.00M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $258.34M | $448.53M | $629.60M | $480.85M | $679.33M | $841.65M | $408.93M | $99.47M | $162.61M | $178.49M |
| Current assets | $206.71M | $341.58M | $475.63M | $381.23M | $602.32M | $767.48M | $343.01M | $84.43M | $145.48M | $161.49M |
| Cash and equivalents | $88.88M | $125.99M | $102.89M | $63.55M | $417.19M | $541.16M | $177.67M | $72.36M | $126.91M | $124.95M |
| Total liabilities | $197.33M | $580.52M | $823.03M | $618.26M | $581.61M | $560.67M | $303.71M | $138.06M | $132.08M | $159.13M |
| Short-term debt | $1.83M | $1.69M | $2.15M | $4.32M | $3.49M | $3.13M | $2.20M | N/A | $3.29M | $5.55M |
| Long-term debt | $37.05M | $264.93M | $226.89M | $471.06M | $408.28M | $404.02M | $178.39M | $103.09M | $101.61M | $100.26M |
| Shareholder equity | $61.01M | -$131.99M | -$193.43M | -$137.42M | $97.73M | $280.97M | $105.21M | -$38.59M | $31.82M | $20.53M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $171.10M | $191.18M | $266.02M | $258.34M | $516.52M | $439.46M | $371.07M | $448.53M | $505.00M | $674.86M | $763.54M | $629.60M |
| Total liabilities | $145.85M | $130.34M | $187.40M | $197.33M | $428.75M | $319.64M | $554.54M | $580.52M | $592.97M | $758.96M | $845.39M | $823.03M |
| Cash and equivalents | $53.49M | $82.92M | $115.24M | $88.88M | $103.35M | $216.89M | $82.41M | $125.99M | $97.69M | $159.24M | $259.77M | $102.89M |
| Shareholder equity | $25.25M | $60.84M | $78.62M | $61.01M | $87.77M | $119.83M | -$183.47M | -$131.99M | -$87.97M | -$84.11M | -$81.84M | -$193.43M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$138.51M | -$20.44M | -$174.88M | -$241.12M | -$37.43M | $154.15M | $28.36M | -$159.27M | -$200.29M | -$252.54M |
| Capital expenditures | $0 | $0 | $286.00K | $2.04M | $1.29M | $7.23M | $1.82M | $789.00K | $4.57M | $6.51M |
| Free cash flow | -$138.51M | -$20.44M | -$175.17M | -$243.16M | -$38.72M | $146.91M | $26.53M | -$160.06M | -$204.86M | -$259.06M |
| Dividends paid | N/A | N/A | N/A | $3.74M | $1.75M | $20.35M | $72.14M | N/A | $0 | $0 |
| Investing cash flow | $375.09M | $230.32M | $144.64M | -$166.85M | -$138.41M | -$14.40M | -$12.73M | -$1.19M | -$4.42M | -$6.51M |
| Financing cash flow | -$273.70M | -$186.97M | $69.60M | $54.33M | $51.88M | $223.95M | $89.37M | $105.42M | $206.79M | $226.18M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$34.02M | -$62.09M | -$57.89M | -$19.72M | -$46.34M | -$46.63M | -$25.83M | $28.61M | -$62.02M | $59.73M | -$46.77M | -$12.94M |
| Capital expenditures | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $34.00K |
| Free cash flow | N/A | N/A | -$57.89M | -$19.72M | -$46.34M | -$46.63M | -$25.83M | $28.61M | -$62.02M | $59.73M | -$46.77M | -$12.97M |
Frequently Asked Questions About CHRS
What is Coherus BioSciences' annual revenue?
Coherus BioSciences reported revenue of $42.17M for the fiscal year ended Dec 31, 2025.
How fast is Coherus BioSciences' revenue growing?
Revenue was up 59.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -41.5%.
Is Coherus BioSciences profitable?
Yes. Coherus BioSciences reported net income of $168.02M for the fiscal year ended Dec 31, 2025, with a net margin of 398.4%.
How much free cash flow does CHRS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$138.51M minus capital expenditures of $0 produced free cash flow of -$138.51M.
How much debt does Coherus BioSciences have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $37.05M, short-term debt of $1.83M and cash and equivalents of $88.88M.
CHRS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors